Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients
NCT ID: NCT05632523
Last Updated: 2025-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2023-12-13
2024-11-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B Cell Lymphocyte in Humoral Rejection and Alloimmunisation
NCT03016455
Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients
NCT04295928
Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
NCT07134491
Rejection Diagnosis in Kidney Transplants Patients
NCT03582436
Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation
NCT03227965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adult patients with renal transplant
Conversion from anticalcineurin to belatacept
Blood sample
Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
urinary sample
Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
urinary sample
Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Renal transplant patient
* Patient converted from an anticalcineurin to belatacept
Exclusion Criteria
* Hemoglobin \< 9g/dL
* Patient under judicial protection
* Pregnant or breastfeeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe GATAULT
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Tours
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DR210053
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.